Literature DB >> 26149442

Quantification of HER2 by Targeted Mass Spectrometry in Formalin-Fixed Paraffin-Embedded (FFPE) Breast Cancer Tissues.

Carine Steiner1, Jean-Christophe Tille2, Jens Lamerz3, Sabine Kux van Geijtenbeek3, Thomas A McKee2, Miro Venturi4, Laura Rubbia-Brandt2, Denis Hochstrasser5, Paul Cutler3, Pierre Lescuyer5, Axel Ducret3.   

Abstract

The ability to accurately quantify proteins in formalin-fixed paraffin-embedded tissues using targeted mass spectrometry opens exciting perspectives for biomarker discovery. We have developed and evaluated a selectedreaction monitoring assay for the human receptor tyrosine-protein kinase erbB-2 (HER2) in formalin-fixed paraffin-embedded breast tumors. Peptide candidates were identified using an untargeted mass spectrometry approach in relevant cell lines. A multiplexed assay was developed for the six best candidate peptides and evaluated for linearity, precision and lower limit of quantification. Results showed a linear response over a calibration range of 0.012 to 100 fmol on column (R(2): 0.99-1.00).The lower limit of quantification was 0.155 fmol on column for all peptides evaluated. The six HER2 peptides were quantified by selected reaction monitoring in a cohort of 40 archival formalin-fixed paraffin-embedded tumor tissues from women with invasive breast carcinomas, which showed different levels of HER2 gene amplification as assessed by standard methods used in clinical pathology. The amounts of the six HER2 peptides were highly and significantly correlated with each other, indicating that peptide levels can be used as surrogates of protein amounts in formalin-fixed paraffin-embedded tissues. After normalization for sample size, selected reaction monitoring peptide measurements were able to correctly predict 90% of cases based on HER2 amplification as defined by the American Society of Clinical Oncology and College of American Pathologists. In conclusion, the developed assay showed good analytical performance and a high agreement with immunohistochemistry and fluorescence in situ hybridization data. This study demonstrated that selected reaction monitoring allows to accurately quantify protein expression in formalin-fixed paraffin-embedded tissues and represents therefore a powerful approach for biomarker discovery studies. The untargeted mass spectrometry data is available via ProteomeXchange whereas the quantification data by selected reaction monitoring is available on the Panorama Public website.
© 2015 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26149442      PMCID: PMC4597152          DOI: 10.1074/mcp.O115.049049

Source DB:  PubMed          Journal:  Mol Cell Proteomics        ISSN: 1535-9476            Impact factor:   5.911


  41 in total

Review 1.  Triple-negative breast cancer.

Authors:  William D Foulkes; Ian E Smith; Jorge S Reis-Filho
Journal:  N Engl J Med       Date:  2010-11-11       Impact factor: 91.245

2.  Options and considerations when selecting a quantitative proteomics strategy.

Authors:  Bruno Domon; Ruedi Aebersold
Journal:  Nat Biotechnol       Date:  2010-07-09       Impact factor: 54.908

3.  Improving the biomarker pipeline.

Authors:  Christoph H Borchers; Carol E Parker
Journal:  Clin Chem       Date:  2010-10-12       Impact factor: 8.327

4.  Multiple reaction monitoring-based, multiplexed, absolute quantitation of 45 proteins in human plasma.

Authors:  Michael A Kuzyk; Derek Smith; Juncong Yang; Tyra J Cross; Angela M Jackson; Darryl B Hardie; N Leigh Anderson; Christoph H Borchers
Journal:  Mol Cell Proteomics       Date:  2009-05-01       Impact factor: 5.911

Review 5.  Proteomic developments in the analysis of formalin-fixed tissue.

Authors:  Ove J R Gustafsson; Georgia Arentz; Peter Hoffmann
Journal:  Biochim Biophys Acta       Date:  2014-10-12

6.  Protein phosphorylation analysis in archival clinical cancer samples by shotgun and targeted proteomics approaches.

Authors:  Angelo Gámez-Pozo; Iker Sánchez-Navarro; Enrique Calvo; Esther Díaz; María Miguel-Martín; Rocío López; Teresa Agulló; Emilio Camafeita; Enrique Espinosa; Juan Antonio López; Manuel Nistal; Juan Ángel Fresno Vara
Journal:  Mol Biosyst       Date:  2011-05-26

7.  Application of selected reaction monitoring for multiplex quantification of clinically validated biomarkers in formalin-fixed, paraffin-embedded tumor tissue.

Authors:  Todd Hembrough; Sheeno Thyparambil; Wei-Li Liao; Marlene M Darfler; Joseph Abdo; Kathleen M Bengali; Stephen M Hewitt; Richard A Bender; David B Krizman; Jon Burrows
Journal:  J Mol Diagn       Date:  2013-05-11       Impact factor: 5.568

8.  Targeted peptide measurements in biology and medicine: best practices for mass spectrometry-based assay development using a fit-for-purpose approach.

Authors:  Steven A Carr; Susan E Abbatiello; Bradley L Ackermann; Christoph Borchers; Bruno Domon; Eric W Deutsch; Russell P Grant; Andrew N Hoofnagle; Ruth Hüttenhain; John M Koomen; Daniel C Liebler; Tao Liu; Brendan MacLean; D R Mani; Elizabeth Mansfield; Hendrik Neubert; Amanda G Paulovich; Lukas Reiter; Olga Vitek; Ruedi Aebersold; Leigh Anderson; Robert Bethem; Josip Blonder; Emily Boja; Julianne Botelho; Michael Boyne; Ralph A Bradshaw; Alma L Burlingame; Daniel Chan; Hasmik Keshishian; Eric Kuhn; Christopher Kinsinger; Jerry S H Lee; Sang-Won Lee; Robert Moritz; Juan Oses-Prieto; Nader Rifai; James Ritchie; Henry Rodriguez; Pothur R Srinivas; R Reid Townsend; Jennifer Van Eyk; Gordon Whiteley; Arun Wiita; Susan Weintraub
Journal:  Mol Cell Proteomics       Date:  2014-01-17       Impact factor: 5.911

9.  Absolute quantitation of Met using mass spectrometry for clinical application: assay precision, stability, and correlation with MET gene amplification in FFPE tumor tissue.

Authors:  Daniel V T Catenacci; Wei-Li Liao; Sheeno Thyparambil; Les Henderson; Peng Xu; Lei Zhao; Brittany Rambo; John Hart; Shu-Yuan Xiao; Kathleen Bengali; Jamar Uzzell; Marlene Darfler; David B Krizman; Fabiola Cecchi; Donald P Bottaro; Theodore Karrison; Timothy D Veenstra; Todd Hembrough; Jon Burrows
Journal:  PLoS One       Date:  2014-07-01       Impact factor: 3.240

Review 10.  Applications of mass spectrometry for quantitative protein analysis in formalin-fixed paraffin-embedded tissues.

Authors:  Carine Steiner; Axel Ducret; Jean-Christophe Tille; Marlene Thomas; Thomas A McKee; Laura Rubbia-Brandt; Alexander Scherl; Pierre Lescuyer; Paul Cutler
Journal:  Proteomics       Date:  2014-03       Impact factor: 3.984

View more
  8 in total

1.  Optimized Protocol for Quantitative Multiple Reaction Monitoring-Based Proteomic Analysis of Formalin-Fixed, Paraffin-Embedded Tissues.

Authors:  Jacob J Kennedy; Jeffrey R Whiteaker; Regine M Schoenherr; Ping Yan; Kimberly Allison; Melissa Shipley; Melissa Lerch; Andrew N Hoofnagle; Geoffrey Stuart Baird; Amanda G Paulovich
Journal:  J Proteome Res       Date:  2016-07-27       Impact factor: 4.466

Review 2.  The clinical impact of recent advances in LC-MS for cancer biomarker discovery and verification.

Authors:  Hui Wang; Tujin Shi; Wei-Jun Qian; Tao Liu; Jacob Kagan; Sudhir Srivastava; Richard D Smith; Karin D Rodland; David G Camp
Journal:  Expert Rev Proteomics       Date:  2015-12-19       Impact factor: 3.940

3.  High HER2 protein levels correlate with increased survival in breast cancer patients treated with anti-HER2 therapy.

Authors:  Paolo Nuciforo; Sheeno Thyparambil; Claudia Aura; Ana Garrido-Castro; Marta Vilaro; Vicente Peg; José Jimenez; Rocio Vicario; Fabiola Cecchi; William Hoos; Jon Burrows; Todd Hembrough; Juan Carles Ferreres; José Perez-Garcia; Joaquin Arribas; Javier Cortes; Maurizio Scaltriti
Journal:  Mol Oncol       Date:  2015-09-15       Impact factor: 6.603

Review 4.  A Timely Shift from Shotgun to Targeted Proteomics and How It Can Be Groundbreaking for Cancer Research.

Authors:  Sara S Faria; Carlos F M Morris; Adriano R Silva; Micaella P Fonseca; Patrice Forget; Mariana S Castro; Wagner Fontes
Journal:  Front Oncol       Date:  2017-02-20       Impact factor: 6.244

5.  The addition of FAIMS increases targeted proteomics sensitivity from FFPE tumor biopsies.

Authors:  Steve Sweet; David Chain; Wen Yu; Philip Martin; Marlon Rebelatto; Andrew Chambers; Fabiola Cecchi; Yeoun Jin Kim
Journal:  Sci Rep       Date:  2022-08-16       Impact factor: 4.996

6.  Quantification of Human Epidermal Growth Factor Receptor 2 by Immunopeptide Enrichment and Targeted Mass Spectrometry in Formalin-Fixed Paraffin-Embedded and Frozen Breast Cancer Tissues.

Authors:  Jacob J Kennedy; Jeffrey R Whiteaker; Laura C Kennedy; Dustin E Bosch; Melissa L Lerch; Regine M Schoenherr; Lei Zhao; ChenWei Lin; Shrabanti Chowdhury; Mark R Kilgore; Kimberly H Allison; Pei Wang; Andrew N Hoofnagle; Geoffrey Stuart Baird; Amanda G Paulovich
Journal:  Clin Chem       Date:  2021-07-06       Impact factor: 12.167

7.  Quantitative proteomic analysis of HER2 expression in the selection of gastric cancer patients for trastuzumab treatment.

Authors:  E An; C-Y Ock; T-Y Kim; K-H Lee; S-W Han; S-A Im; T-Y Kim; W-L Liao; F Cecchi; A Blackler; S Thyparambil; W H Kim; J Burrows; T Hembrough; D V T Catenacci; D-Y Oh; Y-J Bang
Journal:  Ann Oncol       Date:  2017-01-01       Impact factor: 32.976

8.  Quantification of HER1, HER2 and HER3 by time-resolved Förster resonance energy transfer in FFPE triple-negative breast cancer samples.

Authors:  Alexandre Ho-Pun-Cheung; Hervé Bazin; Florence Boissière-Michot; Caroline Mollevi; Joëlle Simony-Lafontaine; Emeline Landas; Jean-Pierre Bleuse; Thierry Chardès; Jean-François Prost; André Pèlegrin; William Jacot; Gérard Mathis; Evelyne Lopez-Crapez
Journal:  Br J Cancer       Date:  2019-12-03       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.